Ergothioneine is a rare dietary amino acid concentrated in mushrooms and made by certain fungi and bacteria. Humans cannot synthesize it, but we absorb it efficiently through a dedicated transporter (SLC22A4), and the body selectively stores it in tissues exposed to oxidative stress—like red blood cells, the eye, and immune cells. Interest in ergothioneine has surged as studies link higher blood levels with healthier aging markers and lower risk profiles for cognitive and cardiovascular decline. Early trials also suggest potential benefits for sleep quality and memory in older adults. This guide explains what ergothioneine does, where it comes from, how to use it, and the safety questions to consider. You will find practical dosage examples drawn from clinical research, a clear overview of benefits and limitations, and an evidence check that separates promising signals from proven outcomes.
Essential Insights: Ergothioneine
- Concentrated antioxidant that accumulates in high-stress tissues via the SLC22A4 transporter.
- Signals for healthy aging: higher plasma levels associate with slower cognitive and functional decline.
- Typical supplemental intake studied: 5–25 mg/day; some trials used 8–20 mg/day for sleep and ~25 mg three times weekly for cognition.
- Safety is favorable overall; evidence still maturing for specific disease outcomes.
- Avoid use or seek medical guidance if you have mushroom allergy, upcoming surgery, or are under oncology care where antioxidants may be restricted.
Table of Contents
- What is ergothioneine and how does it work?
- Proven and promising benefits in humans
- How to take it, forms and dosage
- Absorption, transport, and food sources
- Safety, side effects, and who should avoid
- Evidence check: what we know and do not
What is ergothioneine and how does it work?
Ergothioneine (often abbreviated as “ET” or “EGT”) is a sulfur-containing derivative of histidine—chemically a betaine amino acid. Unlike common antioxidants that react broadly, ergothioneine exists mainly in a stable “thione” form at physiological pH. That chemistry makes it unusually resistant to auto-oxidation and well suited to quenching highly reactive species at the precise sites where damage occurs.
Humans acquire ergothioneine from the diet. The body invests in a specialized transporter, SLC22A4 (also called OCTN1 or the ergothioneine transporter), to pull it from the gut into cells and to conserve it in the kidney. This transporter is highly expressed in tissues that routinely face oxidative or inflammatory stress. That is why ergothioneine tends to concentrate in red blood cell precursors in bone marrow, in immune cells, and in barrier tissues like the eye and the gut. The selective uptake is not just a curiosity—it is a biological hint that the molecule plays an important protective role.
Mechanistically, ergothioneine appears to support cellular resilience in several complementary ways:
- Direct radical scavenging: It reacts rapidly with hydroxyl radicals and deactivates singlet oxygen—two of the most damaging oxidants in biology.
- Redox cycling without pro-oxidant swings: Oxidized forms (like ergothioneine disulfide) can be restored by cellular systems such as ascorbate, glutathione reductase, and thioredoxin reductase, returning the molecule to its protective state.
- Metal chelation: It can bind transition metals that catalyze oxidative reactions, reducing secondary damage.
- Stress-response signaling: Experimental work indicates ergothioneine can activate Nrf2-linked antioxidant pathways, helping cells upregulate their own defense machinery.
- Mitochondrial protection: Animal and cell studies suggest preservation of mitochondrial function under stress, which may link to observed benefits in models of neurodegeneration and ischemia-reperfusion.
Two properties make ergothioneine stand out among dietary antioxidants. First, targeted distribution via SLC22A4 means it accumulates where it is needed. Second, slow excretion and retention mean that blood (especially within red blood cells) can remain elevated for weeks after intake stops. Together, these traits allow modest daily intakes to build meaningful tissue stores over time.
Because humans likely evolved to rely on microbial dietary sources (not internal synthesis), some researchers have proposed ergothioneine as a “longevity vitamin”—not essential for survival in the strict sense, but potentially important for healthy aging when dietary supply is low. That classification remains a hypothesis, yet it reflects a growing body of evidence connecting ergothioneine status with markers of long-term health.
Proven and promising benefits in humans
Ergothioneine’s benefits are best viewed in two tiers: signals from human cohorts and early trials (promising but not definitive) and cell/animal findings (mechanistic support).
Cognitive aging and brain health. Several observational studies show that lower plasma ergothioneine associates with poorer cognition at baseline and faster decline over multi-year follow-up in older adults attending memory clinics. In these cohorts, participants with lower baseline levels tended to show steeper decreases in global cognition and in domains like memory, executive function, and language. Imaging analyses suggest that cerebrovascular disease burden (e.g., white matter hyperintensities) may partially mediate these relationships, hinting that ergothioneine’s vascular protective effects could be important for brain aging.
Early interventional work is emerging. A pilot randomized, double-blind, placebo-controlled trial in older adults with mild cognitive impairment tested 25 mg ergothioneine capsules three times per week for one year. The regimen was well tolerated and associated with improved performance on learning tests and stabilization of neurofilament light chain (a marker of neuronal injury), while the placebo group showed no improvement and rising injury markers. As a pilot, it was small and not definitive, but it strengthens the case to study ergothioneine further for prodromal cognitive decline.
Sleep quality and stress. Sleep research is newer but intriguing. A model-guided clinical program found that 8 mg/day for 16 weeks improved subjective sleep quality versus placebo. Prior exploratory work with 20 mg/day for four weeks in healthy adults also reported better sleep parameters. Animal studies align with these findings: ergothioneine normalized stress-related sleep disruptions and depressive-like sleep changes, likely via antioxidant and anti-inflammatory actions along the gut-brain axis. While sleep outcomes are not yet established across diverse populations, the signal appears consistent enough to merit attention, especially at modest doses.
Cardiometabolic and vascular signals. In large cohort metabolomics analyses, higher plasma ergothioneine associated with lower risk of incident coronary disease and lower cardiovascular and all-cause mortality across decades of follow-up. These associations do not prove causation, but they align with mechanistic data showing endothelial protection, reduced pro-inflammatory signaling, and improved responses to oxidative stress in vascular models.
Skin and barrier function. Human data are limited, but one randomized study using an ergothioneine-rich mushroom strain (providing ~25 mg/day) reported improvements in skin moisture and some facial parameters over several weeks. In vitro and ex vivo work shows UV and gamma-radiation protection to skin cells; this has motivated topical uses, though those are outside the scope of dietary supplementation.
What is not yet proven. There are no large, long-term randomized trials demonstrating prevention of dementia, cardiovascular events, or mortality with ergothioneine supplementation. Observational associations could reflect healthier diets (mushroom consumption, overall diet quality) or other confounders. That said, the convergence of selective biology (the dedicated transporter), pharmacokinetics (retention), and consistent human signals makes ergothioneine an unusually coherent candidate for further clinical testing.
Bottom line: For now, the strongest human evidence supports links to healthier cognitive aging and improved sleep quality at low daily doses, with excellent tolerability in trials. Expect refinements as larger studies report, especially in at-risk older adults and in cardiometabolic cohorts.
How to take it, forms and dosage
Forms available. Supplements typically contain L-ergothioneine (synthetic or fermentation-derived), the same isomer found in foods. Products may be sold as stand-alone capsules or included in “healthy aging,” cognitive, or sleep blends. A few formulas combine ergothioneine with mushroom extracts; check labels for actual milligram content of ergothioneine, which varies widely.
Evidence-informed dosing. Human studies to date suggest a low effective range:
- 5–10 mg/day: Elevates plasma and whole-blood ergothioneine over weeks; useful for steady repletion.
- 8 mg/day for 16 weeks: Improved subjective sleep quality in a randomized, placebo-controlled study.
- 20 mg/day for 4 weeks: Reported improvements in sleep parameters in healthy adults.
- ~25 mg three times per week for one year (≈10.7 mg/day on average): In a pilot RCT in mild cognitive impairment, this schedule was safe and associated with improved learning and stabilized neuronal injury markers.
Practical starting points.
- For general wellness or sleep support, consider 5–10 mg/day for at least 8–12 weeks; assess sleep and daytime function.
- For older adults focusing on cognitive maintenance, 10–15 mg/day (or 25 mg on alternate days) is a reasonable evidence-aligned approach, pending clinician input.
- For diet-first users, see the food section below; pairing a modest supplement with regular mushroom intake is common.
Timing and with food. Ergothioneine absorbs well; it can be taken with or without food. Some users take it in the morning (to avoid evening supplements that could interact with other routines), while those targeting sleep often take it earlier in the day to build steady levels; there is no strong evidence for a specific clock time.
Stacking considerations. Ergothioneine’s profile is complementary to vitamin C, glutathione precursors (e.g., N-acetylcysteine), or magnesium for sleep—but avoid unproven megadoses of overlapping antioxidants. Because ergothioneine is selectively transported and retained, more is not necessarily better; focus on consistency over months.
When to expect effects. Blood levels rise within 1–2 weeks, while red blood cell levels can continue increasing for several weeks even after intake stops. Subjective sleep changes, when they occur, often appear after 4–8 weeks at the studied doses. Cognitive outcomes are slower and are best tracked over months, ideally with structured tests.
Quality tips. Choose brands that specify milligram content of ergothioneine, provide third-party testing, and avoid proprietary blends that obscure dose. If you rely on mushroom powders, recognize that ergothioneine content fluctuates by species and cultivation; a standardized capsule can help you reach consistent intake.
Special populations. See safety notes below if you are pregnant or breastfeeding (evidence supports safety at proposed intakes, but individualized advice is best), have kidney disease, or are advised to avoid antioxidants during chemotherapy or radiation.
Absorption, transport, and food sources
Absorption and conservation. After oral intake, ergothioneine is absorbed in the small intestine primarily via SLC22A4. The same transporter in the kidney reclaims ergothioneine from the filtrate, which is why urinary losses are minimal (typically a few percent). This conservation explains the slow decline in blood levels when intake stops and the steady accumulation in red blood cells and other tissues over time.
Tissue targeting. High expression of SLC22A4 in bone marrow, immune cells, the lens and cornea, and parts of the gastrointestinal tract leads to selective tissue enrichment. Transporter biology supports a “place-and-protect” model: the body actively shuttles ergothioneine to locations with ongoing oxidative or inflammatory challenges.
Food sources. Humans rely on diet because we do not synthesize ergothioneine. The richest sources are foods produced with or by fungi:
- Mushrooms (notably oyster, shiitake, maitake, porcini, and button/crimini): Levels vary widely by species, strain, and growing conditions, but mushrooms consistently outrank other foods.
- Fermented foods: Certain fermentations (e.g., koji-fermented rice bran; fermented shiitake) can be relatively high.
- Spirulina products (Arthrospira) and select plant foods may contain modest amounts, often via microbial associations in soil.
Dietary strategies. If you are food-first, aim for 2–5 servings of mushrooms per week, rotating species. Cooking does not appear to destroy ergothioneine significantly; sautéing or roasting is fine. Because content varies, combining dietary intake with a low-dose supplement can deliver a reliable baseline while keeping your diet diverse and cost-effective.
Transporter variation. Genetic differences in SLC22A4 exist, and some variants show altered transport activity in vitro. While early reports linked certain variants to autoimmune or inflammatory conditions, larger analyses suggest those associations were likely due to linkage with nearby genes rather than SLC22A4 itself. Whether common variants meaningfully change ergothioneine needs or responses in the general population remains an open research question; practically, most people absorb and retain ergothioneine well.
Key takeaways for sourcing:
- Mushrooms are your highest-yield foods for ergothioneine.
- Supplements provide dose certainty; foods provide broader nutrition.
- The body actively retains ergothioneine, so consistent intake over weeks is more important than high single doses.
Safety, side effects, and who should avoid
Overall safety profile. Regulatory reviews in Europe concluded that synthetic L-ergothioneine is safe under proposed uses and levels for the general population, including pregnant and breastfeeding women and young children, based on conservative exposure estimates and large margins of safety. Human pharmacokinetic studies using 5–25 mg/day for one week reported no serious adverse events, minimal urinary loss, and expected rises in blood levels. Longer trials in older adults and sleep studies at 8–20 mg/day reported good tolerability.
Common side effects. In published trials, side effects have been rare and mild (e.g., transient gastrointestinal discomfort or headache) and similar to placebo. Because ergothioneine is selectively transported and tightly conserved, acute intolerance is uncommon.
Interactions and cautions.
- Oncology care: Some clinics advise limiting antioxidant supplements during certain chemotherapies or radiation, as they may theoretically blunt treatment-related oxidative mechanisms. If you are in active treatment, follow your oncology team’s guidance.
- Surgery: Standard pre-operative advice often restricts non-essential supplements for 1–2 weeks before procedures; include ergothioneine in that list.
- Allergy: If you have a mushroom allergy, choose purified L-ergothioneine supplements without mushroom powders.
- Kidney disease: While kidneys conserve ergothioneine, individuals with advanced CKD should review any supplement plan with their nephrology team.
- Polypharmacy: SLC22A4 is not a major drug transporter for common medications, but interactions are under-studied. If you take multiple prescription drugs, start low and inform your clinician.
Pregnancy and lactation. Regulatory assessments support safety within proposed food and supplement intakes. Nonetheless, personalized advice is best in pregnancy; discuss any new supplement—ergothioneine included—with your obstetric provider.
Long-term unknowns. We lack multi-year randomized outcome trials for dementia prevention, cardiovascular events, or mortality. The body’s strong conservation of ergothioneine is reassuring, but it also means that steady long-term use builds stores; doses above the studied range are not justified.
Practical safety tips:
- Select third-party tested products.
- Start at 5–10 mg/day for 2–4 weeks before considering increases.
- Keep your clinician informed, especially if you are older, have chronic conditions, or are changing medications.
Evidence check: what we know and do not
What is well supported now
- Selective transport and retention: The existence of a dedicated transporter (SLC22A4) and strong tissue conservation is firmly established and unusual among dietary antioxidants.
- Pharmacokinetics at low doses: Human dose-ranging work shows that 5–25 mg/day raises plasma and red-blood-cell levels with minimal urinary loss. Blood levels continue to rise for weeks after intake stops, consistent with bone-marrow uptake into maturing red cells.
- Observational links to healthy aging: Multiple cohorts tie higher ergothioneine status to slower cognitive decline and lower cardiometabolic risk over long follow-up.
- Early randomized signals: Small, controlled trials report improved sleep quality and better learning performance or stabilization of neuronal injury markers in older adults at 8–25 mg/day-equivalent.
What remains uncertain
- Hard outcomes: No large-scale trials yet show that supplementation prevents dementia, stroke, or heart attacks.
- Optimal dose and duration: Studies use 8–25 mg/day (or ~25 mg several times per week). Whether very low daily intakes (e.g., 2–4 mg) or higher intakes are better for specific outcomes is untested.
- Who benefits most: People with low baseline levels, higher oxidative stress, or vascular risks may benefit more, but stratified data are limited.
- Transporter genetics: Common SLC22A4 variants with reduced transport activity exist, but their clinical importance is unclear.
How to apply the evidence today
- Treat ergothioneine as a low-dose, long-view nutrient: predictable, conservative dosing (5–15 mg/day) over months fits its biology.
- Combine supplementation with diet: mushroom-forward meals plus a modest capsule can raise and sustain levels without chasing high doses.
- Focus on sleep quality, energy/stress resilience, and age-related cognitive maintenance as the most plausible near-term benefits, while recognizing the evidence is still growing.
Red flags to avoid
- Claims that ergothioneine prevents Alzheimer’s disease or extends lifespan in humans. We do not have those trials.
- Mega-dosing without clinical rationale. The transporter is saturable; more is not necessarily better and may be wasteful.
References
- Ergothioneine: an underrecognised dietary micronutrient required for healthy ageing? 2023 (Review).
- The biology of ergothioneine, an antioxidant nutraceutical 2020 (Review).
- Investigating the efficacy of ergothioneine to delay cognitive decline in mild cognitively impaired subjects: A pilot study 2024 (RCT).
- Low Plasma Ergothioneine Predicts Cognitive and Functional Decline in an Elderly Cohort Attending Memory Clinics 2022 (Prospective cohort).
- Statement on the safety of synthetic l-ergothioneine as a novel food – supplementary dietary exposure and safety assessment for infants and young children, pregnant and breastfeeding women 2017 (Regulatory safety statement).
Disclaimer
This article is for educational purposes only and does not replace personalized medical advice. Ergothioneine is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any new supplement, especially if you are pregnant or breastfeeding, have a medical condition, are preparing for surgery, or are taking prescription medications.
If you found this helpful, please consider sharing it on Facebook, X (formerly Twitter), or your favorite platform, and follow us for future evidence-based guides. Your support helps us continue producing high-quality content.
